Title: New advances of adjuvant chemotherapy in breast cancer
Abstract: It's widely accepted that adjuvant chemotherapy and endocrine treatment significantly improved DDFS and OS in breast cancer . Nowaday, The chemotherapeutic drugs of anthracycline and taxane are used widely in breast cancer. It was proved that taxane alone can get more benefit than anthracycline alone in breast cancer. The combining chemotherapy of anthracycline and taxane can improve clinical outcomes because of their different anticancer mechanism, but how to use them perfectly is a hot topic. Another interesting avenue of investigation regarding adjuvant therapy relates to the utilization of prognostic and predictive biomarkers to quantify risk for recurrence and to identify populations of patients who benefit more or less from treatment in adjuvant chemotherapy of early-Stage breast cancer .
Publication Year: 2005
Publication Date: 2005-01-01
Language: en
Type: article
Access and Citation
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot